ArticleJNCI cancer spectrum2020
Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location.
Article in JNCI cancer spectrum, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review.Cancer biology & medicine · 2024Pooled it
- Evaluating statistical models for overdispersed multiomics data: a multiplex immunofluorescence case study.American journal of epidemiology · 2026Article
- Alcohol consumption and molecular subtypes of colorectal cancer: pooled observational and Mendelian randomization analyses.The American journal of clinical nutrition · 2026Observational
- Sex Differences in the Impact of Obesity on Immunity.Immunological reviews · 2026Review
- Density of T-cell Subsets in Colorectal Cancer in Relation to Disease-Specific Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Differences in the role of Gper1 in colorectal cancer progression depending on sex.Oncology letters · 2025Article
- Biological Aging in Combination with Lifestyle Factors in the Blood-Based Methylome: A Biomarker for Colorectal Cancer Susceptibility in African American Women.Aging and disease · 2025Article
- Light to Moderate Alcohol Consumption and Cancer Incidence: The Norwegian Women and Health Cohort Study.Clinical epidemiology · 2025Article
- Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.British journal of cancer · 2024Article
- Association between somatic microsatellite instability, hypermutation status, and specific T cell subsets in colorectal cancer tumors.Frontiers in immunology · 2024Article
- Body mass index and molecular subtypes of colorectal cancer.Journal of the National Cancer Institute · 2023Article
- Article
- 17β-estradiol Enhances 5-Fluorouracil Anti-Cancer Activities in Colon Cancer Cell Lines.Medical sciences (Basel, Switzerland) · 2022Article
- Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases.International journal of cancer · 2022Article
- Therapeutic Strategies and Potential Actions of Female Sex Steroid Hormones and Their Receptors in Colon Cancer Based on Preclinical Studies.Life (Basel, Switzerland) · 2022Review
- Association Between Smoking and Molecular Subtypes of Colorectal Cancer.JNCI cancer spectrum · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 19 institutions in 7 countries.
Funding
Abstract
backgroundPostmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor location.
methodsWe pooled data on tumor subtypes (microsatellite instability status, CpG island methylator phenotype status,
resultsAmong postmenopausal women, ever HT use was associated with a 38% reduction in overall CRC risk (OR =0.62, 95% CI = 0.56 to 0.69). This association was similar according to microsatellite instability, CpG island methylator phenotype and
conclusionsWe observed a strong inverse association between HT use and overall CRC risk, which may predominantly reflect a benefit of HT use for tumors arising through the adenoma-carcinoma and alternate pathways as well as distal colon and rectal tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.